We note that the X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) CFO, Treasurer & Corporate Secretary, David Kirske, recently sold US$73k worth of stock for US$4.29 per share. On the bright side, that's just a small sale and only reduced their holding by 8.8%.

X4 Pharmaceuticals Insider Transactions Over The Last Year

The Executive Chair Adam Craig made the biggest insider purchase in the last 12 months. That single transaction was for US$250k worth of shares at a price of US$2.90 each. We do like to see buying, but this purchase was made at well below the current price of US$4.00. While it does suggest insiders consider the stock undervalued at lower prices, this transaction doesn't tell us much about what they think of current prices.

You can see the insider transactions (by companies and individuals) over the last year depicted in the chart below. If you click on the chart, you can see all the individual transactions, including the share price, individual, and the date!

X4 Pharmaceuticals is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Insider Ownership Of X4 Pharmaceuticals

For a common shareholder, it is worth checking how many shares are held by company insiders. We usually like to see fairly high levels of insider ownership. Our data suggests X4 Pharmaceuticals insiders own 0.3% of the company, worth about US$1.2m. I generally like to see higher levels of ownership.

What Might The Insider Transactions At X4 Pharmaceuticals Tell Us?

An insider hasn't bought X4 Pharmaceuticals stock in the last three months, but there was some selling. But we take heart from prior transactions. Still, insiders don't own a great deal of the stock. So the company doesn't look great on this analysis. While it's good to be aware of what's going on with the insider's ownership and transactions, we make sure to also consider what risks are facing a stock before making any investment decision. Be aware that X4 Pharmaceuticals is showing 4 warning signs in our investment analysis, and 1 of those shouldn't be ignored...

Of course X4 Pharmaceuticals may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.